Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients

Cancers

Wen-Juei Jeng¹  Wei Teng¹  Yen-Chun Liu¹  Chien-Wei Su² 

[1] Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Medical Center College of Medicine, Chang Gung University, Taiwan NO 5, Fu-Hsing Street, Kuei Shan, Taoyuan City 33305, Taiwan;Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taiwan. No.201, Sec. 2, Shipai Rd., Peitou District, Taipei 11217, Taiwan;

关键词: carcinogenesis;    cirrhosis;    direct acting antiviral agents;    interferon;    nucleos(t)ide analogues;    sustained virologic response;   

DOI  :  10.3390/cancers13071729

来源: DOAJ

【 摘 要 】

Hepatocellular carcinoma (HCC) ranks as a leading cause of common cancer and cancer-related death. The major etiology of HCC is due to chronic hepatitis virus including HBV and HCV infections. Scheduled HCC surveillance in high risk populations improves the early detection rate and the feasibility of curative treatment. However, high HCC recurrence rate still accounts for the poor prognosis of HCC patients. In this article, we critically review the pathogenesis of viral hepatitis-related hepatocellular carcinoma and the evidence of tertiary prevention efficacy by current available antiviral treatment, and discuss the knowledge gap in viral hepatitis-related HCC tertiary prevention.

【 授权许可】

Unknown